Topic: prostate cancer

Erleada

4. Erleada

Erleada was greenlighted for non-metastatic, castration-resistant prostate cancer months before its decision date, giving it a big head start on market share compared to its main competitor, Pfizer and Astellas’ Xtandi, which was approved for the same indication in July.